AR077969A1 - Derivados de (tio)morfolina comomoduladores de s1p - Google Patents
Derivados de (tio)morfolina comomoduladores de s1pInfo
- Publication number
- AR077969A1 AR077969A1 ARP100103116A ARP100103116A AR077969A1 AR 077969 A1 AR077969 A1 AR 077969A1 AR P100103116 A ARP100103116 A AR P100103116A AR P100103116 A ARP100103116 A AR P100103116A AR 077969 A1 AR077969 A1 AR 077969A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- optionally substituted
- halogen
- phenyl
- substituted
- Prior art date
Links
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 title abstract 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 10
- 125000001153 fluoro group Chemical group F* 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000005843 halogen group Chemical group 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 2
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 abstract 2
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 abstract 2
- 125000002947 alkylene group Chemical group 0.000 abstract 2
- 125000000304 alkynyl group Chemical group 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 125000002911 monocyclic heterocycle group Chemical group 0.000 abstract 2
- -1 phenoxy, benzyl Chemical group 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 125000004860 4-ethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])C([H])([H])[H] 0.000 abstract 1
- 229910018828 PO3H2 Inorganic materials 0.000 abstract 1
- QUANOCBMLUVNHV-UHFFFAOYSA-N acetonitrile;2-(2-phenylmorpholin-4-yl)ethanol Chemical compound CC#N.C1N(CCO)CCOC1C1=CC=CC=C1 QUANOCBMLUVNHV-UHFFFAOYSA-N 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 abstract 1
- 150000001602 bicycloalkyls Chemical group 0.000 abstract 1
- 239000004305 biphenyl Chemical group 0.000 abstract 1
- 235000010290 biphenyl Nutrition 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 1
- 125000002993 cycloalkylene group Chemical group 0.000 abstract 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 125000005647 linker group Chemical group 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 abstract 1
- 125000004299 tetrazol-5-yl group Chemical group [H]N1N=NC(*)=N1 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
- C07D265/32—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
- C07F9/6533—Six-membered rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente se refiere a derivados de tio(morfolina) que tienen la formula (1): en la cual: R1 está seleccionado a partir de ciano, alquinilo(C2-4), alquilo(C1-4), cicloalquilo(C3-6), cicloalquenilo(C4-6), bicicloalquilo(C6-8), grupo bicíclico(C8-10), cada uno sustituido opcionalmente con alquilo(C1-4), fenilo, bifenilo, naftilo, cada uno opcionalmente sustituido con uno o más sustítuyentes seleccionados en forma independiente a partir de halogeno, alquilo(C1-4) opcionalmente sustituido con uno o más átomos de fluor, alquinilo(C2-4), alcoxilo(C1-4) opcionalmente sustituido con uno o más átomos de fluor, amino, dialquil(C1-4) amino, -SO2- alquilo(C1-4), -CO-alquilo(C1-4), -CO-alquilo(C1-4), -NH-CO-alquilo(C1-4) y cicloalquilo(C3-6); fenilo sustituido con fenoxilo, bencilo, benciloxilo, feniletilo o heterociclo monocíclico, cada uno opcionalmente sustituido con alquilo(C1-4), heterociclo monocíclico opcionalmente sustituido con halogeno, alquilo(C1-4) o con fenilo opcionalmente sustituido con alquilo(C1-4); y heterociclo bicíclico opcionalmente sustituido con alquilo(C1-4); A está seleccionado a partir de -CO-O-, -O-CO-, -NH-CO-, -CO-NH-, -C=C-, -CCH3-O- y el grupo de enlace -Y-(CH2)n-X- en el cual: Y está unido a R1 y seleccionado a partir de un enlace -O-, -S-, -SO-, -SO2-, -CH2-O-, -CO-, -O-CO-, -CO-O-, -CO-NH-, -NH-CO-, -C=C- y -C:::C-; n es un entero de 1 a 10; y X está unido al grupo fenileno/piridilo y está seleccionado a partir de un enlace -O-, -S-, -SO-, -SO2-, -NH-, -CO-, -C=C- y -C:::C-; la estructura de anillo B contiene opcionalmente un átomo de nitrogeno; R2 es H, alquilo(C1-4) opcionalmente sustituido con uno o más átomos de fluor, alcoxilo(C1-4) opcionalmente sustituido con uno o más átomos de fluor o halogeno; y R3 es alquileno(C1-4)-R5 en el cual el grupo alquileno puede estar sustituido con (CH2)2 para formar una fraccion ciclopropilo o uno o dos átomos halogeno o R3 es cicloalquileno(C3-6)-R5 o -CO-CH2-R5 en la cual R5 es -OH, -PO3H2, -OPO3H2, -COOH, -COO-alquilo(C1-4) o tetrazol-5-ilo; R4 es H o alquilo(C1-4); R6 es uno o más sustituyentes seleccionados en forma independiente a partir de H, alquilo(C1-4) u oxo; W es -O-, -S-, -SO- o -SO2-; o una sal, solvato o hidrato del mismo aceptable en el campo farmacéutico, con la condicion de que el derivado de la formula (1) no es 2-(4-etilfenil)-4-morfolina etanol o 4-[4-(2-hidroxietil)-2-morfolinil]bencen acetonitrilo o una sal, solvato o hidrato de los mismos aceptables en el campo farmacéutico. Los compuestos tienen afinidad por los receptores S1P y pueden ser utilizados en el tratamiento, alivio o prevencion de enfermedades y condiciones mediadas por el receptor S1P.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09169075 | 2009-08-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR077969A1 true AR077969A1 (es) | 2011-10-05 |
Family
ID=41361253
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100103116A AR077969A1 (es) | 2009-08-31 | 2010-08-26 | Derivados de (tio)morfolina comomoduladores de s1p |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US9045441B2 (es) |
| EP (1) | EP2473490B1 (es) |
| JP (1) | JP5933436B2 (es) |
| KR (1) | KR101767882B1 (es) |
| CN (1) | CN102548976B (es) |
| AR (1) | AR077969A1 (es) |
| AU (1) | AU2010288477B8 (es) |
| CA (1) | CA2772169C (es) |
| CR (1) | CR20120153A (es) |
| DO (1) | DOP2012000053A (es) |
| EC (1) | ECSP12011695A (es) |
| ES (1) | ES2452550T3 (es) |
| IL (1) | IL218208A (es) |
| MX (1) | MX2012002534A (es) |
| NZ (1) | NZ598300A (es) |
| PE (1) | PE20121280A1 (es) |
| PL (1) | PL2473490T3 (es) |
| RU (1) | RU2557233C2 (es) |
| SG (1) | SG178902A1 (es) |
| TW (1) | TW201113263A (es) |
| UA (1) | UA106994C2 (es) |
| UY (1) | UY32858A (es) |
| WO (1) | WO2011023795A1 (es) |
| ZA (1) | ZA201201446B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY32858A (es) | 2009-08-31 | 2011-03-31 | Abbott Healthcare Products Bv | Derivados de (tio)morfolina como moduladores de sip |
| TWI522361B (zh) | 2010-07-09 | 2016-02-21 | 艾伯維公司 | 作為s1p調節劑的稠合雜環衍生物 |
| TWI543984B (zh) | 2010-07-09 | 2016-08-01 | 艾伯維公司 | 作為s1p調節劑的螺-哌啶衍生物 |
| TW201206893A (en) | 2010-07-09 | 2012-02-16 | Abbott Healthcare Products Bv | Bisaryl (thio) morpholine derivatives as S1P modulators |
| US8802673B2 (en) | 2011-03-24 | 2014-08-12 | Hoffmann-La Roche Inc | Heterocyclic amine derivatives |
| US9029370B2 (en) | 2011-06-10 | 2015-05-12 | Hoffmann-La Roche Inc. | Substituted benzamide derivatives |
| JP2016500706A (ja) * | 2012-11-07 | 2016-01-14 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ピラジン誘導体 |
| EP2925721B1 (en) * | 2012-11-20 | 2017-06-07 | Biogen MA Inc. | S1p and/or atx modulating agents |
| CN105949142B (zh) * | 2016-05-21 | 2018-03-27 | 南华大学 | 具有抗抑郁活性的单一手性化合物及其制备方法和应用 |
| JP2018095631A (ja) * | 2016-12-14 | 2018-06-21 | 東ソー株式会社 | フェノール誘導体製造方法 |
| US20180230105A1 (en) | 2017-01-13 | 2018-08-16 | Regents Of The University Of Minnesota | Therapeutic compounds |
| AU2020373047A1 (en) | 2019-10-31 | 2022-05-19 | ESCAPE Bio, Inc. | Solid forms of an S1P-receptor modulator |
| AR127592A1 (es) * | 2021-11-08 | 2024-02-07 | Hoffmann La Roche | Hidrogenación catalítica de nitrocompuestos aromáticos |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH072848A (ja) | 1993-04-23 | 1995-01-06 | Sankyo Co Ltd | モルホリンおよびチオモルホリン誘導体 |
| JP4152002B2 (ja) * | 1996-08-27 | 2008-09-17 | 興和創薬株式会社 | ２−フェニルモルホリン−５−オン誘導体およびそれを含む医薬組成物 |
| US6380387B1 (en) | 1999-12-06 | 2002-04-30 | Hoffmann-La Roche Inc. | 4-Pyrimidinyl-n-acyl-l phenylalanines |
| AU2001246916B2 (en) | 2000-04-21 | 2004-10-07 | Shionogi & Co., Ltd. | Oxadiazole derivatives having anticancer effects |
| DK1631557T3 (da) | 2003-06-12 | 2007-05-07 | Btg Int Ltd | Cyklisk hydroxylamin som psykoaktive forbindelser |
| RU2390519C2 (ru) * | 2003-08-29 | 2010-05-27 | Оно Фармасьютикал Ко., Лтд. | Соединение, способное к связыванию с рецептором s1p, и его фармацевтическое применение |
| ES2527117T3 (es) * | 2003-08-29 | 2015-01-20 | Ono Pharmaceutical Co., Ltd. | Compuesto capaz de unirse a receptor SIP y uso farmacéutico del mismo |
| US7550485B2 (en) | 2003-10-14 | 2009-06-23 | Wyeth | Substituted N-heterocycle derivatives and methods of their use |
| GB0329498D0 (en) | 2003-12-19 | 2004-01-28 | Novartis Ag | Organic compounds |
| TW200538433A (en) * | 2004-02-24 | 2005-12-01 | Irm Llc | Immunosuppressant compounds and compositiions |
| GB0409744D0 (en) | 2004-04-30 | 2004-06-09 | Pfizer Ltd | Novel compounds |
| BRPI0510453A (pt) | 2004-04-30 | 2007-10-30 | Warner Lambert Co | composto substituìdos com morfolina para o tratamento de distúrbios do sistema nervoso central |
| AU2005299851B2 (en) * | 2004-10-22 | 2011-03-17 | Merck Sharp & Dohme Corp. | 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as S1P receptor agonists |
| WO2006047159A1 (en) * | 2004-10-22 | 2006-05-04 | Agrinomics Llc | Generation of plants with altered oil content |
| KR101079914B1 (ko) | 2006-01-27 | 2011-11-04 | 에프. 호프만-라 로슈 아게 | 중추신경계 장애를 위한 4-이미다졸 유도체의 용도 |
| AU2007209381A1 (en) | 2006-01-27 | 2007-08-02 | F. Hoffmann-La Roche Ag | Use of substituted 2-imidazole of imidazoline derivatives |
| SG171635A1 (en) | 2006-02-28 | 2011-06-29 | Helicon Therapeutics Inc | Therapeutic piperazines as pde4 inhibitors |
| BRPI0716598A2 (pt) | 2006-09-08 | 2013-12-10 | Novartis Ag | Derivados de (hetero) arilsulfonamida de n-biarila úteis no tratamento de doenças medidas por interações de linfócitos |
| AU2007334436A1 (en) * | 2006-12-15 | 2008-06-26 | Abbott Laboratories | Novel oxadiazole compounds |
| US20100144729A1 (en) * | 2007-02-02 | 2010-06-10 | Rolf Baenteli | Coumarin derivatives |
| UY32858A (es) | 2009-08-31 | 2011-03-31 | Abbott Healthcare Products Bv | Derivados de (tio)morfolina como moduladores de sip |
| CN101812058B (zh) | 2010-04-13 | 2012-03-21 | 湖南大学 | 吲哚美辛2-芳基吗啉乙酯及其制备方法与应用 |
-
2010
- 2010-08-26 UY UY0001032858A patent/UY32858A/es not_active Application Discontinuation
- 2010-08-26 AR ARP100103116A patent/AR077969A1/es unknown
- 2010-08-27 TW TW099128939A patent/TW201113263A/zh unknown
- 2010-08-27 CA CA2772169A patent/CA2772169C/en not_active Expired - Fee Related
- 2010-08-27 RU RU2012112477/04A patent/RU2557233C2/ru not_active IP Right Cessation
- 2010-08-27 MX MX2012002534A patent/MX2012002534A/es active IP Right Grant
- 2010-08-27 PL PL10745659T patent/PL2473490T3/pl unknown
- 2010-08-27 AU AU2010288477A patent/AU2010288477B8/en not_active Ceased
- 2010-08-27 UA UAA201203923A patent/UA106994C2/uk unknown
- 2010-08-27 KR KR1020127008115A patent/KR101767882B1/ko not_active Expired - Fee Related
- 2010-08-27 SG SG2012013793A patent/SG178902A1/en unknown
- 2010-08-27 ES ES10745659.2T patent/ES2452550T3/es active Active
- 2010-08-27 WO PCT/EP2010/062552 patent/WO2011023795A1/en not_active Ceased
- 2010-08-27 US US13/393,497 patent/US9045441B2/en not_active Expired - Fee Related
- 2010-08-27 JP JP2012526075A patent/JP5933436B2/ja not_active Expired - Fee Related
- 2010-08-27 CN CN201080042681.8A patent/CN102548976B/zh not_active Expired - Fee Related
- 2010-08-27 EP EP10745659.2A patent/EP2473490B1/en active Active
- 2010-08-27 NZ NZ598300A patent/NZ598300A/xx not_active IP Right Cessation
- 2010-08-27 PE PE2012000276A patent/PE20121280A1/es not_active Application Discontinuation
-
2012
- 2012-02-20 IL IL218208A patent/IL218208A/en not_active IP Right Cessation
- 2012-02-27 ZA ZA2012/01446A patent/ZA201201446B/en unknown
- 2012-02-27 EC ECSP12011695 patent/ECSP12011695A/es unknown
- 2012-02-29 DO DO2012000053A patent/DOP2012000053A/es unknown
- 2012-03-27 CR CR20120153A patent/CR20120153A/es unknown
-
2015
- 2015-03-30 US US14/673,614 patent/US9273017B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR077969A1 (es) | Derivados de (tio)morfolina comomoduladores de s1p | |
| AR074089A1 (es) | Antagonistas de cicloalcano (b) azaindol de los receptores de la postaglandina d2 | |
| AR077975A1 (es) | Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina | |
| AR047076A1 (es) | Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas | |
| EA201990902A1 (ru) | Ингибиторы тирозинкиназы брутона | |
| AR119728A1 (es) | Derivados de 1,1-dioxido de 3-amino-4h-benzo[e][1,2,4]tiadiazina como inhibidores de mrgx2 | |
| CL2012000999A1 (es) | Compuestos derivados de pirazoloespirocetona sustituida, inhibidores de acetil-coa carboxilasa; composicion farmaceutica que los comprende; uso para tratar o retrasar la progresion o el inicio de diabetes tipo 2, higado graso no alcoholico (hgna) o la resistencia hepatica a la insulina. | |
| AR059622A1 (es) | Quinolonas utiles como inhibidores de la sintetasa del oxido nitrico inducibles | |
| AR075597A1 (es) | Derivados de indol como antagonistas de receptores crth2, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del asma y otras enfermedades alergicas . | |
| AR065499A1 (es) | Inhibidores de serino proteasas.composiciones farmaceuticas | |
| UY31027A1 (es) | Derivados de tetrahidroindol y tetrahidroindazol | |
| AR056886A1 (es) | Compuestos de pirrolopiridina sustituida inhibidores de quinasas, composiciones farmaceuticas que los contienen y usos en el tratamiento del cancer | |
| EA201492170A1 (ru) | Новые замещенные в цикле n-пиридиниламиды в качестве ингибиторов киназ | |
| PE20091450A1 (es) | INHIBIDORES DE LA ESTEAROIL-CoA-DESATURASA | |
| ES2496592T3 (es) | Proceso para la preparación de Imatinib y compuestos intermedios del mismo | |
| EA202192900A1 (ru) | Модуляторы пути интегрированной реакции на стресс | |
| EA202190586A1 (ru) | N-замещенные диоксоциклобутениламино-3-гидроксипиколинамиды, приемлемые в качестве ингибиторов ccr6 | |
| PE20191006A1 (es) | Compuestos de aza-indazol para usar en lesiones de tendones y/o ligamentos | |
| ECSP24050151A (es) | Derivados de 4-fenil-2-(1h-1,2,3-triazol-4-il)piperidin-4-ol como inhibidores de apol1 y métodos para usar los mismos | |
| AR082136A1 (es) | Derivados heterociclicos fusionados como moduladores s1p | |
| ECSP055745A (es) | Derivados de 1-(4-bencil-piperazin-1-il)-3-fenil-propenona | |
| CL2009001146A1 (es) | Compuestos derivados de 5-(5-(2-(3,5-bis(trifluorometil)fenil)-n,2-dimetilpropanoamida)-4-(4-fluoro-2-metilfenil)piridin-2-il)pirrolidin-2-carboxamida, antagonistas de los receptores nk-1; composicion farmaceutica; y uso del compuesto para el tratamiento de la depresion; ansiedad, trastornos del sueño o emesis. | |
| PE20211456A1 (es) | Compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados para el tratamiento y prevencion del cancer de higado | |
| AR082137A1 (es) | Derivados de bisaril(tio)morfolina como modulares s1p y composiciones farmaceuticas que los contienen | |
| AR075160A1 (es) | Derivados de aril y/o heteroaril piperidinas sustituidas, medicamentos que las contienen, proceso para prepararlas y uso de las mismas para el tratamiento de trastornos neurologicos y neuropsiquiatricos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |